About: Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver
Creator	Ebensen, Thomas Bruder, Dunja Klopfleisch, Robert Müller, Andreas Lienenklaus, Stefan Gereke, Marcus Knolle, Percy Philipsen, Lars Riese, Peggy Stegemann-Koniszewski, Sabine Volckmar, Julia Wohlleber, Dirk Gruber, Achim Guzman, Carlos
source	Medline; PMC
abstract	Hepatotropic viruses such as hepatitis C virus cause life-threatening chronic liver infections in millions of people worldwide. Targeted in vivo antigen-delivery to cross-presenting dendritic cells (DCs) has proven to be extraordinarily efficient in stimulating antigen-specific T cell responses. To determine whether this approach would as well be suitable to induce local antiviral effector T cells in the liver we compared different vaccine formulations based on either the targeting of DEC-205 or TLR2/6 on cross-presenting DCs or formulations not involving in vivo DC targeting. As read-outs we used in vivo hepatotropic adenovirus challenge, histology and automated multidimensional fluorescence microscopy (MELC). We show that targeted in vivo antigen delivery to cross-presenting DCs is highly effective in inducing antiviral CTLs capable of eliminating virus-infected hepatocytes, while control vaccine formulation not involving DC targeting failed to induce immunity against hepatotropic virus. Moreover, we observed distinct patterns of CD8(+) T cell interaction with virus-infected and apoptotic hepatocytes in the two DC-targeting groups suggesting that the different vaccine formulations may stimulate distinct types of effector functions. Our findings represent an important step toward the future development of vaccines against hepatotropic viruses and the treatment of patients with hepatic virus infection after liver transplantation to avoid reinfection.
has issue date	2017-03-07(xsd:dateTime)
bibo:doi	10.1038/srep43985
bibo:pmid	28266658
has license	cc-by
sha1sum (hex)	7e232c192b439ef6a844be6a2f40bbbae64469fb
schema:url	https://doi.org/10.1038/srep43985
resource representing a document's title	Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver
has PubMed Central identifier	PMC5339819
has PubMed identifier	28266658
schema:publication	Sci Rep
resource representing a document's body	covid:7e232c192b439ef6a844be6a2f40bbbae64469fb#body_text
is schema:about of	named entity 'AUTOMATED' named entity 'ANTIGEN DELIVERY' named entity 'T CELL' named entity 'IN VIVO' named entity 'CROSS' named entity 'TO AVOID' named entity 'HEPATOTROPIC' named entity 'CAPABLE' named entity 'OUR' named entity 'STIMULATE' named entity 'APOPTOTIC' named entity 'OBSERVED' named entity 'INDUCE' named entity 'NOT INVOLVING' named entity 'READ' named entity 'PATIENTS' named entity 'INFECTED' named entity 'PRESENTING' named entity 'EFFECTOR' named entity 'T CELL' named entity 'targeted' named entity 'DCs' named entity 'vaccine' named entity 'robust' named entity 'DENDRITIC CELLS' named entity 'IMMUNITY' named entity 'DCS' named entity 'INDUCING' named entity 'INTERACTION' named entity 'VIRUS' named entity 'USED' named entity 'CHALLENGE' named entity 'VIRUS INFECTION' named entity 'REPRESENT' named entity 'DIFFERENT' named entity 'GROUPS' named entity 'VACCINES' named entity 'FLUORESCENCE MICROSCOPY' named entity 'TREATMENT' named entity 'HIGHLY' named entity 'FINDINGS' named entity 'IMPORTANT' named entity 'OPEN' named entity 'ANTIGEN DELIVERY' named entity 'ANTIVIRAL' named entity 'ELICITS' named entity 'ROBUST' named entity 'TARGETED' named entity 'CELL-MEDIATED IMMUNITY' named entity 'TARGETING' named entity 'CD8' named entity 'MULTIDIMENSIONAL' named entity 'CONTROL' named entity 'ADENOVIRUS' named entity 'OUTS' named entity 'VACCINE' named entity 'TARGETED' named entity 'HEPATIC' named entity 'STEP' named entity 'PATTERNS' named entity 'DEVELOPMENT' named entity 'LIVER' named entity 'HEPATOCYTES' named entity 'FAILED' named entity 'HISTOLOGY' named entity 'DISTINCT' named entity 'FUNCTIONS' named entity 'REINFECTION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software